AXON has been the subject of a number of other reports. BidaskClub upgraded Axovant Sciences from a strong sell rating to a sell rating in a research note on Saturday, September 23rd. Chardan Capital reiterated a sell rating and issued a $8.00 price target on shares of Axovant Sciences in a research note on Thursday, September 14th. Piper Jaffray Companies reiterated a hold rating on shares of Axovant Sciences in a research note on Friday, November 10th. Evercore ISI assumed coverage on Axovant Sciences in a research note on Friday, September 8th. They issued an outperform rating and a $30.00 price target for the company. Finally, Robert W. Baird reiterated a hold rating and issued a $6.00 price target on shares of Axovant Sciences in a research note on Wednesday, November 1st. Four equities research analysts have rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $14.13.
Shares of Axovant Sciences (NASDAQ AXON) opened at $5.16 on Friday. Axovant Sciences has a 12-month low of $4.60 and a 12-month high of $27.98. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94.
Axovant Sciences (NASDAQ:AXON) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12). equities research analysts predict that Axovant Sciences will post -2.16 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Axovant Sciences Ltd. (AXON) Earns “Hold” Rating from Oppenheimer Holdings, Inc.” was originally posted by Stock Observer and is the property of of Stock Observer. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.thestockobserver.com/2017/11/15/axovant-sciences-ltd-axon-earns-hold-rating-from-oppenheimer-holdings-inc.html.
Several large investors have recently made changes to their positions in AXON. FMR LLC raised its stake in shares of Axovant Sciences by 968.5% in the second quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock worth $167,794,000 after purchasing an additional 6,558,462 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Axovant Sciences in the second quarter worth about $47,854,000. OxFORD Asset Management LLP raised its stake in shares of Axovant Sciences by 842.1% in the third quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock worth $5,838,000 after purchasing an additional 777,505 shares during the last quarter. Capital Research Global Investors raised its stake in shares of Axovant Sciences by 21.8% in the second quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock worth $80,094,000 after purchasing an additional 619,226 shares during the last quarter. Finally, Eagle Asset Management Inc. purchased a new position in shares of Axovant Sciences in the third quarter worth about $4,471,000.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.